SITC Resource Library

The Society for Immunotherapy of Cancer (SITC) hosted the Targeting Myeloid Cells in Immuno-Oncology Workshop Program during the 38^th Annual Meeting & Pre-Conference Programs on November 2, 2023. Available here are the presentation slides and video from “Session 3: Regulation of Myeloid Cell Metabolism in Cancer” as permitted by presenters.

Program Organizers

• Dmitry I. Gabrilovich, MD, PhD – AstraZeneca

• Jennifer L. Guerriero, PhD – Brigham and Women's Hospital

• Judith A. Varner, PhD – University of California, San Diego

Target Audience

The target audience for this program includes basic, translational, and clinical researchers from all work settings with an interest in myeloid cell biology and myeloid cell-based therapeutics for cancer.

Program Description

As part of the 38^th Annual Meeting & Pre-Conference Programs (SITC 2023), the SITC Targeting Myeloid Cells in Immuno-Oncology pre-conference program provides an opportunity for an in-depth discussion on a specific topic in the field. This program on myeloid cells helps SITC to advance the science and application of cancer immunotherapy by providing novel, relevant and engaging content to basic, translational, and clinical researchers and physicians. This program will explore the recent advances in the field including underlying biology and diversity of myeloid cells, myeloid signaling pathways, regulation of myeloid cell metabolism in cancer, therapeutic approaches to target myeloid cells in immuno-oncology and the potential for the use of myeloid cell biomarkers for stratification of patients. The program aims to bring the field together to educate and promote myeloid cell targeting with the overall goal of making the tumor microenvironment more permissive and expanding tumor specific T cells. Armed with a deeper biological understanding of myeloid cell biology within the tumor and strategies to modulate the function and activity of myeloid cells, attendees will be equipped to effectively target myeloid cells for anti-cancer therapy, potentially impacting clinical care and leading to better patient outcomes.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe characteristics of myeloid cells and summarize the biological mechanisms underlying myeloid cell-mediated immunosuppression in the tumor microenvironment

• Detail approaches to modulate myeloid cell function and promote anti-cancer immunity

• Analyze cutting-edge basic, translational, and clinical studies of myeloid cells to incorporate new research and techniques into clinical applications for cancer immunotherapy 

To view the entire program schedule (including presenter permission to post) please click here.